Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review and guideline summary without systematic search or meta-analysis.
PubMed 21680989 · doi:10.3810/pgm.2011.07.2304
What was done
This narrative review examined updated clinical guidelines from the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) for the diagnosis and treatment of type 2 diabetes mellitus, using a case-based format to illustrate treatment tailoring.
What was found
The abstract reports guideline thresholds rather than primary empirical numbers. Both organizations established an HbA1c diagnostic cutoff of >6.5% (in addition to fasting glucose or oral glucose tolerance testing) and recommended initiating metformin at diagnosis. They differed in treatment intensification triggers (HbA1c ≥7% for ADA/EASD vs >6.5% for AACE/ACE) and preferred second-line options: ADA/EASD prioritized a tiered approach using sulfonylureas and basal insulin, whereas AACE/ACE stratified by baseline HbA1c and included dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 agonists, thiazolidinediones, α-glucosidase inhibitors, sulfonylureas, and glinides.
Why it matters
It highlights points of consensus and divergence between major clinical practice algorithms for managing type 2 diabetes, particularly regarding glycemic thresholds for therapy escalation and drug class selection.
Limits
This is a narrative review with no original trial data, meta-analytic pooling, or defined search methodology. The algorithms discussed reflect guidelines from 2011 and do not capture subsequent cardiovascular outcome trials, newer drug approvals, or modern guideline revisions.
Cited by
- context The American Association of Clinical Endocrinologists advises against relying solely on HbA1c for the diagnosis of diabetes because hemoglobin variants, liver disease, kidney disease, and pregnancy can alter HbA1c levels.